Zacks Investment Research upgraded shares of Alimera Sciences (NASDAQ:ALIM) from a sell rating to a hold rating in a report published on Monday, January 8th.
According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “
Several other analysts have also recently commented on ALIM. ValuEngine cut Alimera Sciences from a sell rating to a strong sell rating in a report on Sunday, December 3rd. HC Wainwright reaffirmed a buy rating and set a $5.00 price target on shares of Alimera Sciences in a research note on Wednesday, November 22nd. Finally, Cowen reissued a buy rating on shares of Alimera Sciences in a research note on Thursday, November 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Alimera Sciences has a consensus rating of Hold and an average price target of $3.38.
Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. sell-side analysts predict that Alimera Sciences will post -0.27 EPS for the current fiscal year.
An institutional investor recently raised its position in Alimera Sciences stock. PNC Financial Services Group Inc. grew its holdings in Alimera Sciences, Inc. (NASDAQ:ALIM) by 24.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 180,300 shares of the biopharmaceutical company’s stock after buying an additional 35,200 shares during the period. PNC Financial Services Group Inc. owned 0.28% of Alimera Sciences worth $251,000 at the end of the most recent quarter. 41.78% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This article was first posted by BBNS and is owned by of BBNS. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/markets/alimera-sciences-alim-lifted-to-hold-at-zacks-investment-research/1819024.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.